-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 28, Chia Tai Tianqing Pharmaceutical Group submitted a 4-type generic listing application for iopromide injection
.
This product is a contrast agent owned by Bayer, with global sales of more than 300 million euros in 2021.
Currently, only the original research is imported in China
.
Chengdu Better Pharmaceutical will be the first to apply for generic listing in 2021, and Chia Tai Tianqing Pharmaceutical Group will be the second to apply for production
.
Figure 1: The latest product status of Chia Tai Tianqing Pharmaceutical Group Source: CDE official website Figure 2: Bayer's sales of iopromide (unit: 100 million yuan) Source: Minet.
com China's public medical institutions terminal competition In 2020, the market size of terminal contrast media in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) has exceeded 15 billion yuan, and iopromide is the TOP4 variety.
Currently, only Bayer has been approved.
Imports and sales exceeded 1.
2 billion yuan, with an increase of more than 20% in the first half of 2021
.
In February 2021, Chengdu Beite Pharmaceutical was the first to submit a Category 4 generic application for iopromide injection, and in April this year, it submitted a marketing application with an acceptance number, which is currently under review and approval
.
Figure 3: Sources of contrast agents approved by Chia Tai Tianqing Pharmaceutical Group: The new version database of Minet.
com Chia Tai Tianqing Pharmaceutical Group won the first contrast agent disodium gadoxetate injection in 2019, and the sales of this product after its launch Soaring, in the first half of 2021, the growth rate in the terminals of public medical institutions in China is as high as 132.
81%; in 2020, the company's iodixanol injection was approved for listing, and the iopromide injection declared for listing this time is expected to become the company's third product contrast agent
.
Source: CDE official website, Minet database
.
This product is a contrast agent owned by Bayer, with global sales of more than 300 million euros in 2021.
Currently, only the original research is imported in China
.
Chengdu Better Pharmaceutical will be the first to apply for generic listing in 2021, and Chia Tai Tianqing Pharmaceutical Group will be the second to apply for production
.
Figure 1: The latest product status of Chia Tai Tianqing Pharmaceutical Group Source: CDE official website Figure 2: Bayer's sales of iopromide (unit: 100 million yuan) Source: Minet.
com China's public medical institutions terminal competition In 2020, the market size of terminal contrast media in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) has exceeded 15 billion yuan, and iopromide is the TOP4 variety.
Currently, only Bayer has been approved.
Imports and sales exceeded 1.
2 billion yuan, with an increase of more than 20% in the first half of 2021
.
In February 2021, Chengdu Beite Pharmaceutical was the first to submit a Category 4 generic application for iopromide injection, and in April this year, it submitted a marketing application with an acceptance number, which is currently under review and approval
.
Figure 3: Sources of contrast agents approved by Chia Tai Tianqing Pharmaceutical Group: The new version database of Minet.
com Chia Tai Tianqing Pharmaceutical Group won the first contrast agent disodium gadoxetate injection in 2019, and the sales of this product after its launch Soaring, in the first half of 2021, the growth rate in the terminals of public medical institutions in China is as high as 132.
81%; in 2020, the company's iodixanol injection was approved for listing, and the iopromide injection declared for listing this time is expected to become the company's third product contrast agent
.
Source: CDE official website, Minet database
